Myriad Genetics to Present Seven Studies at the 2019 National Society of Genetic Counselors Annual Meeting
October 28 2019 - 7:05AM
Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular
diagnostics and precision medicine, today announced that it will
present results from seven studies at the 2019 National Society of
Genetic Counselors (NSGC) annual meeting being held Nov. 5–8, 2019
in Salt Lake City."We are excited to present new data from seven
studies at this year’s NSGC meeting," said Susan Manley, MS, CGC,
MBA, senior vice president of Medical Services at Myriad Genetics.
“Our presentations highlight the company’s commitment to advancing
precision medicine in oncology and women’s health.” A list of
presentations at 2019 NSGC is below. Please visit Myriad
Genetics at booth #711 to learn more about our leading portfolio of
precision medicine products. Follow Myriad on Twitter via
@myriadgenetics and follow meeting news by using the hashtag
#NSGC19.
Featured Presentations at 2019 NSGC |
Myriad Product |
Abstract |
Author |
Poster Details |
myRisk® Hereditary Cancer
|
RNA Research Program Continues to be a Valuable Tool in
Variant Reclassification |
Susana San Roman |
Poster (A-94)Tuesday, Nov. 5, 20195:45-7:00 p.m. |
Clinical Utility of Testing for PALB2, ATM, CHEK2, NBN, BRIP1,
RAD51C, and RAD51D: Management Changes and Patient Adherence to
Provider Recommendations |
Katie Johansen Taber |
Poster (A-97)Tuesday, Nov. 5, 20195:45-7:00 p.m. |
|
Foresight®
Carrier Screen |
Fragile X Carrier Screening Accompanied by Genetic Consultation has
Clinical Utility in Populations Beyond Those Recommended by
Guidelines |
Katie Johansen Taber |
Podium (C-08)Thursday, Nov. 7, 201910:35-10:50 a.m. |
Classifying the Severity of Conditions on an Expanded
Carrier Screening Panel |
Aishwarya Arjunan |
Poster (C-329)Thursday, Nov. 7, 20191:20-2:35 p.m. |
Minimizing Results Delivery Time for Couples Undergoing Carrier
Screening by Using a Tandem-Submission-with-Partner-Reflex (“Tandem
Reflex”) Strategy |
Aishwarya Arjunan |
Poster (C-330)Thursday, Nov. 7, 20191:20-2:35 p.m. |
|
PrequelTM
Prenatal Screen |
WGS-based NIPS Without a Fetal Fraction Threshold: What are the
Clinical Outcomes of No-Calls? |
Susan Hancock |
Poster (A-334)Tuesday, Nov. 5, 20195:45-7:00 p.m. |
Expanded Aneuploidy Analysis Reveals Trisomy 2: Evidence of Rare
Aneuploidy via NIPS Provides Opportunity for Focused Care |
Susan Hancock |
Poster (C-315)Thursday, Nov. 7, 20191:20-2:35 p.m. |
|
About Myriad
myRisk® Hereditary CancerThe Myriad myRisk Hereditary
Cancer test uses an extensive number of sophisticated technologies
and proprietary algorithms to evaluate 35 clinically significant
genes associated with eight hereditary cancer sites including:
breast, colon, ovarian, endometrial, pancreatic, prostate and
gastric cancers and melanoma.
About
Foresight® Carrier ScreenThe Myriad Foresight
Carrier Screen is designed to maximize detection of at-risk couples
for serious, prevalent, and clinically-actionable conditions.
Foresight has a rigorous disease selection that focuses on 175+
conditions that provides meaningful information to patients.
Additionally, Foresight offers superior technology with unmatched
detection rates for the vast majority of genes on the panel
(>99% across ethnicities) which means patients can trust both
positive and negative results.
About PrequelTM Prenatal ScreenThe
Myriad Prequel Prenatal Screen is a noninvasive prenatal screen
that uses cell-free DNA (cfDNA) to determine if a pregnancy is at
an increased risk for chromosome abnormalities, such as Down
syndrome. Prequel has been shown to be superior to screening
methods that use maternal age, ultrasound and serum screening.
Additionally, Prequel has a lower false-positive rate and
false-negative rate than these other methods. The Prequel Prenatal
Screen can be ordered with the Foresight Carrier Screen and offered
to all women, including those with high body mass index, and ovum
donor or a twin pregnancy.
About Myriad GeneticsMyriad
Genetics Inc. is a leading precision medicine company dedicated to
being a trusted advisor transforming patient lives worldwide with
pioneering molecular diagnostics. Myriad discovers and
commercializes molecular diagnostic tests that: determine the risk
of developing disease, accurately diagnose disease, assess the risk
of disease progression, and guide treatment decisions across six
major medical specialties where molecular diagnostics can
significantly improve patient care and lower healthcare
costs. Myriad is focused on five critical success
factors: building upon a solid hereditary cancer foundation,
growing new product volume, expanding reimbursement coverage for
new products, increasing RNA kit revenue internationally and
improving profitability with Elevate 2020. For more
information on how Myriad is making a difference, please visit the
Company's website: www.myriad.com.Myriad, the Myriad logo, BART,
BRACAnalysis, Colaris, Colaris AP, myPath, myRisk, Myriad myRisk,
myRisk Hereditary Cancer, myChoice, myPlan, BRACAnalysis CDx, Tumor
BRACAnalysis CDx, myChoice HRD, EndoPredict, Vectra, GeneSight,
riskScore, Prolaris, Foresight and Prequel are trademarks or
registered trademarks of Myriad Genetics, Inc. or its wholly owned
subsidiaries in the United States and foreign countries. MYGN-F,
MYGN-G.
Safe Harbor StatementThis press
release contains "forward-looking statements" within the meaning of
the Private Securities Litigation Reform Act of 1995, including
statements relating to data being presented for its genetic tests
at the 2019 National Society of Genetic Counselors Meeting being
held Nov. 5–8, 2019 in Salt Lake City; and the Company's strategic
directives under the caption "About Myriad Genetics." These
"forward-looking statements" are based on management's current
expectations of future events and are subject to a number of risks
and uncertainties that could cause actual results to differ
materially and adversely from those set forth in or implied by
forward-looking statements. These risks and uncertainties
include, but are not limited to: the risk that sales and profit
margins of our molecular diagnostic tests and pharmaceutical and
clinical services may decline; risks related to our ability to
transition from our existing product portfolio to our new tests,
including unexpected costs and delays; risks related to decisions
or changes in governmental or private insurers’ reimbursement
levels for our tests or our ability to obtain reimbursement for our
new tests at comparable levels to our existing tests; risks related
to increased competition and the development of new competing tests
and services; the risk that we may be unable to develop or achieve
commercial success for additional molecular diagnostic tests and
pharmaceutical and clinical services in a timely manner, or at all;
the risk that we may not successfully develop new markets for our
molecular diagnostic tests and pharmaceutical and clinical
services, including our ability to successfully generate revenue
outside the United States; the risk that licenses to the technology
underlying our molecular diagnostic tests and pharmaceutical and
clinical services and any future tests and services are terminated
or cannot be maintained on satisfactory terms; risks related to
delays or other problems with operating our laboratory testing
facilities and our healthcare clinic; risks related to public
concern over genetic testing in general or our tests in particular;
risks related to regulatory requirements or enforcement in the
United States and foreign countries and changes in the structure of
the healthcare system or healthcare payment systems; risks related
to our ability to obtain new corporate collaborations or licenses
and acquire new technologies or businesses on satisfactory terms,
if at all; risks related to our ability to successfully integrate
and derive benefits from any technologies or businesses that we
license or acquire; risks related to our projections about our
business, results of operations and financial condition; risks
related to the potential market opportunity for our products and
services; the risk that we or our licensors may be unable to
protect or that third parties will infringe the proprietary
technologies underlying our tests; the risk of patent-infringement
claims or challenges to the validity of our patents or other
intellectual property; risks related to changes in intellectual
property laws covering our molecular diagnostic tests and
pharmaceutical and clinical services and patents or enforcement in
the United States and foreign countries, such as the Supreme Court
decision in the lawsuit brought against us by the Association for
Molecular Pathology et al; risks of new, changing and competitive
technologies and regulations in the United States and
internationally; the risk that we may be unable to comply with
financial operating covenants under our credit or lending
agreements; the risk that we will be unable to pay, when due,
amounts due under our credit or lending agreements; and other
factors discussed under the heading "Risk Factors" contained in
Item 1A of our most recent Annual Report on Form 10-K for the
fiscal year ended June 30, 2019, which has been filed with the
Securities and Exchange Commission, as well as any updates to those
risk factors filed from time to time in our Quarterly Reports on
Form 10-Q or Current Reports on Form 8-K. All information in
this press release is as of the date of the release, and Myriad
undertakes no duty to update this information unless required by
law.
Media
Contact: |
Ron
Rogers |
Investor
Contact: |
Scott
Gleason |
|
(801) 584-3065 |
|
(801) 584-1143 |
|
rrogers@myriad.com |
|
sgleason@myriad.com |
Myriad Genetics (NASDAQ:MYGN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Myriad Genetics (NASDAQ:MYGN)
Historical Stock Chart
From Apr 2023 to Apr 2024